Zealand Pharma
Logotype for Zealand Pharma

Zealand Pharma (ZEAL) investor relations material

Zealand Pharma Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Zealand Pharma
Jefferies Global Healthcare Conference summary16 Nov, 2026

Metabolic Frontier strategy

  • Around one year into the 2030 strategy, progress includes late-stage obesity programs with Roche and Boehringer, rare-disease advances, a Cambridge, Massachusetts research site opened in September, and partnerships supporting a goal of 10 new metabolic-health clinical programs.

  • Glepaglutide was approved in Europe; a Phase III study is intended to support a later FDA submission. CHI NDA submission was planned for later in the quarter, with potential approval next year.

Petrelintide and amylin strategy

  • ZUPREME-1 and ZUPREME-2 data support a potential profile of double-digit weight loss with placebo-like tolerability to date; management sees ease of starting and staying on treatment as a key future differentiator.

  • Management views amylins as potential first-choice therapies in a patient journey, with combinations or more burdensome treatments added when greater weight loss is needed.

  • Amylin’s effect on insulin sensitivity may suit early or recent-onset diabetes and potentially prevention; ZUPREME-2 showed no weight-loss penalty in diabetes like the 30%-50% reduction cited for GLP-1s.

  • A Phase II study of petrelintide with Roche’s enicepatide, a GLP-1/GIP, was expected to start within weeks; the combination is positioned to pursue higher weight loss and address obesity-related comorbidities.

  • Further amylin innovation includes combinations and alternative administration routes; these programs are a few years behind petrelintide.

Survodutide

  • The SYNCHRONIZE-CVOT non-inferiority study showed hazard ratios of 0.84-0.9, which management said supported cardiovascular safety; survodutide is eightfold more active on GLP-1 than glucagon.

  • Management attributed up to 20% dropouts in earlier studies to a fixed titration protocol; Boehringer changed titration protocols in December 2025, and the LIVERAGE MASH study was expected to read out next year.

  • SYNCHRONIZE-MASLD showed complete liver-fat normalization in 6 of 10 patients; management also cited muscle loss of 10% versus up to 30% with other modalities.

  • Boehringer is studying survodutide in F2/F3 MASH and cirrhotic patients; management cited MASH in 35% of people with obesity or overweight and excess liver fat in 75%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Zealand Pharma earnings date

Logotype for Zealand Pharma
Q4 202625 Feb, 2027
Zealand Pharma
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Zealand Pharma earnings date

Logotype for Zealand Pharma
Q4 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Zealand Pharma, a biotechnology company, engages in discovery, development, and commercialization of peptide therapeutics for metabolic diseases, gastrointestinal diseases and diseases of the central nervous system in Denmark.